Important new data from EORTC trials to be presented at ESMO 2022
5 Sep 2022
EORTC will present significant new results, updates, and future EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer at the ESMO 2022 conference which will take place on September 9 in Paris. Once again, immunotherapy plays a leading role, as do patients’ quality of life studies. Eight abstracts were accepted, with four oral presentations, a proffered paper, and three poster displays.
EORTC data accepted at ESMO:
Cancer type | Abstract Title | Abstract Number/Presentation Details |
---|---|---|
Lung cancer | LBA51 – Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial | Abstract #LBA51 Proffered Paper Session Sunday, 11 September at 14:45 |
Testicular cancer | 512MO – Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database | Abstract #512MO Mini-Oral Session Sunday 11 September at 15:50 |
Melanoma | LBA44 – Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase 3 trial | Abstract #LBA44 Mini-Oral Session Monday, 12 September at 09:10 |
Lung cancer | 930MO – PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091 | Abstract #930MO Mini-Oral Session Monday, 12 September at 14:50 |
Soft tissue and bone sarcoma | 1491MO – New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis | Abstract #1491MO Mini-Oral Session Monday, 12 September at 15:20 |
Soft tissue sarcoma | 1526TiP – TOLERANCE: An EORTC STBSG-QLG-ETF 3-arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin alone three weekly or doxorubicin weekly or cyclophosphamide plus predniso(lo)ne treatment | Abstract #1526TiP Poster display |
Melanoma | 804P – Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial | Abstract #804P Poster display |
Head and neck cancer | 706TiP – Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma, and with T1, N0 hypopharyngeal carcinoma | Abstract #706TiP Poster display |
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023